Predictive technique could help determine breast cancer therapies
Stephen FellerATLANTA, Oct. 5 (UPI) -- Researchers at the Georgia Institute of Technology have developed a predictive model that can provide doctors with a predictive "invasiveness index" for cancer.
ConclusionNone of the treatment methods applied ensured a full release of the restriction within the shoulder and upper limb. The deficits observed may constitute a serious disorder of the musculoskeletal system; therefore, a clinical study of biomechanical parameters of the shoulder joint may be an important control of patients’ functional status after breast cancer treatment.
Abstract Breast cancer stem cells (BCSCs) are a small population of tumor-initiating cells that express stem cell-associated markers. In recent years, their properties and mechanisms of regulation have become a focus for intense research due to their intrinsic resistance to conventional cancer therapies. This review describes breast cancer stem cell origin, signaling pathways involved in self-renewal, such as Wnt, Notch and Hedgehog, biomarkers linked to stemness, and the role of sex steroid hormones on BCSC regulation. PMID: 30095060 [PubMed - as supplied by publisher]
(University of East Anglia) A new cancer therapy using nanoparticles to deliver a combination therapy direct to cancer cells could be on the horizon.Using nanoparticles to get drugs directly into a tumor is a growing area of cancer research. The technology developed at UEA is the first of its kind to use nanoparticles to deliver two drugs in combination to target cancer cells. The therapy has been shown to make breast cancer and prostate cancer tumors more sensitive to chemotherapy.
Conclusions: History of alendronate use is associated with a lower likelihood of bone metastases in postmenopausal women with early breast cancer. Oral bisphosphonate treatment could be sufficient for reducing the risk of bone metastases.
In conclusion, we visualized that the synthesized DTX-nanomicelles can be used as an anticancer drug delivery system considering their useful biocompatibility and excellent physicochemical properties.Graphical abstract
Abstract BMI-1 (B-lymphoma Mo-MLV insertion region 1) is a key protein partner in polycomb repressive complex 1 (PRC1) that helps in maintaining the integrity of the complex. It is also a key player in ubiquitination of histone H2A which affects gene expression pattern involved in various cellular processes such as cell proliferation, growth, DNA repair, apoptosis and senescence. In many cancers, Overexpression of BMI1correlates with advanced stages of disease, aggressive clinicopathological behavior, poor prognosis resistance to radiation and chemotherapy. BMI1 is emerging as a key player in EMT, chemo-resistance...
×. Güniz Küçükgüzel Cyclooxygenase enzymes play a vital role in inflammatory pathways in the human body. Apart from their relation with inflammation, the additional involvement of COX-2 enzyme with cancer activity was recently discovered. In some cancer types the level of COX-2 enzyme is increased indicating that this enzyme could be a suitable target for cancer therapy. Based on these findings, we have synthesized some new diflunisal thiosemicarbazides and 1,2,4-triazoles and tested them against androgen-independent prostate adenocarcinoma (PC-3), colon carcinoma (HCT-116), human breast canc...
With a new artificial intelligence (AI) algorithm, planning for radiation therapy...Read more on AuntMinnie.comRelated Reading: Can AI best quantitative MRI in prostate lesions? Breast cancer follow-up imaging varies widely SNMMI: Early prostate cancer therapy extends lives SNMMI: Fluciclovine-PET changes prostate treatment SNMMI: New therapy aids patients with neuroendocrine tumors
Conclusion: There is a lack of conclusive evidence regarding the benefits of acupuncture for the treatment of breast cancer survivors in Korea. More rigorous RCTs are necessary in the future to establish stronger clinical evidence regarding the use of acupuncture to better reflect the clinical context of Korea.
CONCLUSIONS: FRα is overexpressed in high-grade TNBC and post-chemotherapy residual tumors. It participates in cancer cell signaling and presents a promising target for therapeutic strategies such as antibody-drug conjugates, or passive immunotherapy priming Fc-mediated anti-tumor immune cell responses. PMID: 30068707 [PubMed - as supplied by publisher]